从机制角度看，钠-葡萄糖协同转运蛋白2抑制剂作为2型糖尿病、高血压和高尿酸血症的有效治疗方法 - Suppr

SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective.

作者信息

Rashid Sulthan Al, Balasubramanian Rajkapoor, Maideen Naina Mohamed Pakkir

机构信息

Department of Pharmacology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India.

Department of Pharmacology, J.K.K. Nattraja College of Pharmacy, Komarapalayam 638 183, India.

出版信息

Curr Drug Saf. 2025;20(4):399-401. doi: 10.2174/0115748863344964241106051256.

DOI:10.2174/0115748863344964241106051256

PMID:39582224

Abstract

摘要

相似文献

SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective.从机制角度看，钠-葡萄糖协同转运蛋白2抑制剂作为2型糖尿病、高血压和高尿酸血症的有效治疗方法

Curr Drug Saf. 2025;20(4):399-401. doi: 10.2174/0115748863344964241106051256.

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。

BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂治疗慢性肾脏病成人患者：临床实践指南。

BMJ. 2024 Oct 1;387:e080257. doi: 10.1136/bmj-2024-080257.

Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.比较 SGLT-2 抑制剂与 DPP-4 抑制剂作为 2 型糖尿病患者二甲双胍的附加治疗：系统评价和荟萃分析。

Diabetes Metab. 2018 Mar;44(2):112-120. doi: 10.1016/j.diabet.2018.01.017. Epub 2018 Feb 7.

Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.不同钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的安全性比较：一项随机对照试验的系统评价和网络荟萃分析。

Front Endocrinol (Lausanne). 2023 Aug 28;14:1238399. doi: 10.3389/fendo.2023.1238399. eCollection 2023.

GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.2 型糖尿病血糖控制安全性和疗效的系统评价和网络荟萃分析。

PLoS One. 2019 Jun 25;14(6):e0217701. doi: 10.1371/journal.pone.0217701. eCollection 2019.

Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.不同推荐剂量的钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的比较安全性：一项系统评价和随机临床试验的网络荟萃分析。

Front Endocrinol (Lausanne). 2023 Nov 10;14:1256548. doi: 10.3389/fendo.2023.1256548. eCollection 2023.

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。

BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.

The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists.2 型糖尿病管理的演变：SGLT-2 抑制剂和 GLP-1 受体激动剂的血糖控制及其他方面。

J Osteopath Med. 2023 Nov 3;124(3):127-135. doi: 10.1515/jom-2023-0179. eCollection 2024 Mar 1.

Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白（SGLT）2抑制剂用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。

Cochrane Database Syst Rev. 2016 Apr 21;4(4):CD012106. doi: 10.1002/14651858.CD012106.pub2.

本文引用的文献

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status.SGLT2 抑制剂对心脏和肾脏的影响，无论是否存在糖尿病。

Int J Mol Sci. 2023 Sep 18;24(18):14243. doi: 10.3390/ijms241814243.

Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂的使用与痛风风险：系统评价和荟萃分析。

Front Endocrinol (Lausanne). 2023 May 23;14:1158153. doi: 10.3389/fendo.2023.1158153. eCollection 2023.

Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: a new meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病合并高血压患者血压控制的疗效和安全性评估：一项新的荟萃分析

Diabetol Metab Syndr. 2023 Jun 7;15(1):118. doi: 10.1186/s13098-023-01092-z.

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的安全性概况：简要总结。

Front Cardiovasc Med. 2022 Sep 21;9:1010693. doi: 10.3389/fcvm.2022.1010693. eCollection 2022.

Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review).钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂对动脉僵硬度和血管衰老的影响——我们目前了解多少？（一篇叙述性综述）

Life (Basel). 2022 May 27;12(6):803. doi: 10.3390/life12060803.

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.SGLT2 抑制剂的心脏-肾脏保护机制概述。

Int J Mol Sci. 2022 Mar 26;23(7):3651. doi: 10.3390/ijms23073651.

Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis.钠-葡萄糖协同转运蛋白 2 抑制剂的作用机制及其对心肾轴的有益影响。

Can J Physiol Pharmacol. 2022 Feb;100(2):93-106. doi: 10.1139/cjpp-2021-0399.

Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review.钠-葡萄糖协同转运蛋白2抑制剂的作用机制：综述

Front Med (Lausanne). 2021 Dec 20;8:777861. doi: 10.3389/fmed.2021.777861. eCollection 2021.

SGLT-2 inhibitors as cardio-renal protective agents.钠-葡萄糖协同转运蛋白 2 抑制剂作为心脏-肾脏保护剂。

Metabolism. 2022 Feb;127:154937. doi: 10.1016/j.metabol.2021.154937. Epub 2021 Nov 19.

SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?钠-葡萄糖协同转运蛋白2抑制剂：2型糖尿病治疗的明星药物？

Diseases. 2020 May 11;8(2):14. doi: 10.3390/diseases8020014.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献